Led · Series E · Jan 2024

Founded in 2017, Devoted Health aims to “treat everyone like family” by unifying advanced data and AI with world-class clinical and service excellence on a single care platform. The company bundles its in-house tech stack, Devoted Medical clinical services, health insurance products, and dedicated service Guides to offer consistent, proactive, and individualized healthcare at scale. As of January 2026, Devoted serves more than 466,000 members, a 121% year-over-year increase, and operates across 29 states. The model has earned high recognition from the Centers for Medicare & Medicaid Services, with 100% of rated members enrolled in plans scoring 4 Stars or higher on key quality measures such as statin therapy, post-discharge medication reconciliation, breast-cancer screening, and osteoporosis management. Additional CMS data show 96% of members are in plans rated 4 Stars or higher for blood-pressure control and 97% for cholesterol medication adherence. Member experience is similarly strong: 98% of members are in plans with 4-Star-plus Health Plan Ratings, 95% enjoy 4-Star-plus Customer Service scores, and 93% of surveyed members trust Devoted to fulfill its care commitments. These quality and satisfaction metrics underpin the firm’s rapid growth and reinforce its strategy of redefining healthcare delivery through integrated, data-driven care.

Participated · Seed · Jun 2021

The Black Brain Trust (TBBT) has developed the Equity in Action (EIA) Score, a proprietary scoring methodology that quantifies equity across more than 130 metrics for for-profit companies, government agencies, and nonprofits. The company offers a detailed equity report and business intelligence software that tracks key performance indicators to drive improvement. TBBT plans to implement AI into its platform and hire a product manager to accelerate product development. The firm is also creating a version of its business intelligence platform tailored for diversity, equity, and inclusion consultants. Leadership does not intend to operate as a consultancy; instead the company aims to provide data-driven tools to enable DEI work. Fearless and The Harbor Bank of Maryland are beta testing the EIA Score and monitoring platform.

Participated · Series D · May 2021

Akili Interactive develops prescription digital therapeutics, including EndeavorRx, the first-and-only FDA‑cleared treatment delivered through a video game experience for children with ADHD. EndeavorRx is built on Akili’s Selective Stimulus Management Engine (SSME) and uses adaptive algorithms to target attentional control systems. The company plans to scale go-to-market efforts to bring EndeavorRx to families and healthcare professionals, expand its global footprint in ADHD and beyond, and advance a pipeline of prescription digital therapeutics for chronic and acute cognitive disorders. Akili emphasizes clinical validation, citing positive results in prospective randomized, controlled trials and extensive clinical studies. Financially, the company announced $160M in combined equity and debt financing—$110M Series D equity and a credit facility of up to $50M with Silicon Valley Bank—and reports total equity funding to date of $230M. The funding is intended to support commercialization, technology development, clinical research, and international expansion. Akili develops prescription digital medicines that embed targeted stimuli into immersive action video game experiences to treat conditions across neurology and psychiatry. Its lead program, AKL-T01 for pediatric ADHD, is under FDA review following positive pivotal study topline results announced in December 2017. If cleared, AKL-T01 would be the first prescription video game to treat a medical condition and the first prescription digital medicine for children with ADHD. The company has additional programs in Major Depressive Disorder, multiple sclerosis and various inflammatory diseases, and expects results from a Phase 2 MDD study and an MS pilot by the end of 2018. Akili is also developing complementary clinical monitors and measurement-based care applications. The company was founded by PureTech Health and is advancing its platform with recent equity financing. Akili Interactive develops prescription digital treatments that deliver therapeutic activity through action video game experiences. The company is building a broad pipeline of programs on its patented technology platform to treat cognitive deficits and symptoms across neurology and psychiatry, including ADHD, major depressive disorder, autism spectrum disorder and various inflammatory diseases. Its lead candidate is AKL‑T01 and it is also developing complementary clinical monitors and measurement‑based care applications. Akili was founded by PureTech Health and is led by CEO Eddie Martucci, Ph.D. The company used the financing to advance digital treatment candidates through regulatory milestones, prepare for commercial launch, and to broaden its product pipeline, including programs in depression and multiple sclerosis. Akili builds clinically validated cognitive treatments and assessments delivered through an action video‑game interface, based on its Project: EVO platform licensed from Dr. Adam Gazzaley at UCSF. The company is clinical‑stage and is conducting a pivotal STARS‑ADHD trial of Project: EVO in pediatric ADHD with plans to seek FDA approval if results are favorable. Akili has multiple clinical studies across ADHD, autism spectrum disorder, depression, Alzheimer’s disease, and traumatic brain injury, and has expanded into neurodegeneration indications including Parkinson’s disease, major depressive disorder, and multiple sclerosis. The platform is designed to target core neurological processing and can adapt difficulty in real time for remote use without physician calibration. Akili plans to use the new funds to support and expand clinical development into new areas, increase focus on neurodegeneration, and build out its commercial infrastructure as it nears market with late‑stage products. The company was founded by PureTech Health together with neuroscientists and game designers and has strategic partnerships with Pfizer and Autism Speaks and investment from Shire PLC. Akili develops mobile software-based treatments and monitors designed to function as action video games, targeting cognitive disorders with adaptive, medical-grade software. Its lead product candidate, Project: EVO, is licensed from Dr. Adam Gazzaley's lab at UCSF and was previously published as a Nature cover story. The platform targets cognitive interference processing and adapts difficulty in real time to allow wide-ranging ability levels to use the product without physician calibration or extra hardware. Akili is conducting multiple clinical trials across pediatric ADHD, autism spectrum disorder (in collaboration with Autism Speaks), depression, Alzheimer’s disease (in collaboration with Pfizer) and traumatic brain injury. A recent open-label pilot in pediatric ADHD showed improvements in attention, inhibition and working memory, and the company plans a large randomized pivotal study with results expected in 2017. The company announced $30.5 million in new equity investments to support further clinical development and to build commercial infrastructure toward potential FDA clearance and a planned product launch in 2017.

Participated · Series D · Mar 2021

Atai Life Sciences is a mental health-focused biotech developing therapies in the psychiatric/mental health space. The company has a sizable portfolio and recently reassessed its programs. As part of that reassessment it has pruned its pipeline and exited partnerships. Atai has taken on a $175M loan as it reorganizes. Management says it is concentrating resources on looming data readouts from remaining programs. The company frames these moves as planning for the long haul. atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds to treat depression, anxiety, addiction, and other mental health disorders. The company acquires, incubates and develops therapeutics using funding, technology, and scientific and regulatory expertise, with a focus on psychedelic therapy and drugs with differentiated safety profiles. atai is led by Christian Angermayer and Florian Brand (CEO & co-founder) and operates from Berlin with offices in New York. The company plans to use its new capital to expand and develop its diverse drug candidate pipeline and enabling technologies. It also intends to continue advancing current clinical developments and to scale its team to deliver key milestones. Financially, atai closed a $157M Series D financing to support these efforts. ATAI Life Sciences is a global biotechnology company developing psychedelic and non-psychedelic compounds to treat depression, anxiety, addiction, and other mental health disorders. Its model acquires and incubates programs across multiple entities, combining funding, platform technologies, and scientific and regulatory expertise to accelerate therapeutic development. ATAI focuses on advancing both drug candidates and platform tools with the aim of treating and ultimately preventing mental health disorders. Proceeds from the recent financing will primarily fund pre-clinical and clinical development, expand ATAI's pipeline, and further advance its platform technologies. Management expects the funding to provide runway for several near-term milestones, including Phase 2 data readouts for arketamine in treatment-resistant depression and ibogaine in opioid use disorder, plus completion of Phase 1 and initiation of Phase 2 trials in four other programs. ATAI was founded in 2018 and is headquartered in Berlin, with offices in New York and San Diego. ATAI Life Sciences is a global biotech platform that uses a decentralized, big-data approach to accelerate early-stage drug development for mental health disorders. Founded in 2018 by Christian Angermayer, Lars Wilde and Florian Brand, the company focuses on paradigm-shifting and formerly stigmatized compounds with prior evidence of efficacy and safety in humans. Its portfolio includes Innoplexus, which delivers big data and AI solutions that ATAI uses for in-house discovery, and ATAI is the largest investor in COMPASS Pathways, which is developing psilocybin therapy for treatment-resistant depression. In January ATAI acquired Perception Neuroscience and is developing an arketamine therapy for neuropsychiatric diseases. The company cites an initial focus on addressing depression — affecting more than 300 million people, with roughly 100 million treatment-resistant cases — and plans to use its platform to expand the pipeline and acquire additional compounds. ATAI is based in Berlin, London and New York and recently closed a $43 million Series B to fund platform technology, pipeline development, and acquisitions.